Toward an online cognitive and emotional battery to predict treatment remission in depression

Neuropsychiatric Disease and Treatment

Volumn 11, Issue , 2015, Pages 517-531

  Gordon, Evian ^a   Rush, A John ^b   Palmer, Donna M ^c,d   Braund, Taylor A ^c   Rekshan, William ^a  

^a Brain Resource International Database   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c Brain Resource Ltd   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Antidepressant medication; Biomarkers; Cognitive tests; Depression; Treatment prediction; Treatment selection

Indexed keywords

ESCITALOPRAM; SERTRALINE; VENLAFAXINE;

16 ITEM QUICK INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY SELF REPORT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; COGNITION; COGNITIVE TEST BATTERY; CONTROLLED STUDY; EMOTION; EMOTIONAL TEST BATTERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEASUREMENT ACCURACY; MENTAL PERFORMANCE; NEUROPSYCHOLOGICAL TEST; ONLINE SYSTEM; OUTPATIENT DEPARTMENT; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE;

EID: 84924104214     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S75975     Document Type: Article

References (40)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095–3105.
2. World Health Organization. The global burden of disease: 2004 update. Geneva: WHO; 2008.
3. World Health Organization [homepage on the Internet]. Mental Health Atlas 2011. Geneva, Switzerland: WHO; c2011. Available from: http://www.who.int/mental_health/publications/mental_health_atlas_2011/en/index.html. Accessed 8 September 2014.
4. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917.
5. Rush AJ, Kraemer HC, Sackeim HA, et al. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology. 2006;31(9):1842–1853.
6. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40.
7. Thase ME, Rush AJ. Treatment-resistant depression. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: fourth generation of progress. New York: Raven Press; 1995:1081–1097.
8. Taylor BP, Bruder GE, Stewart JW, et al. Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients. Am J Psychiatry. 2006;163(1):73–78.
9. O’Leary D, Costello F, Gormley N, Webb M. Remission onset and relapse in depression. An 18-month prospective study of course for 100 first admission patients. J Affect Disord. 2000;57(1–3):159–171.
10. Rush AJ. STAR*D: what have we learned? Am J Psychiatry. 2007;164(2):201–204.
11. Bagby RM, Ryder AG, Cristi C. Psychosocial and clinical predictors of response to pharmacotherapy for depression. J Psychiatry Neurosci. 2002;27(4):250–257.
12. Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv. 2009;60(11):1439–1445.
13. Kuk AY, Li J, Rush AJ. Recursive subsetting to identify patients in the STAR*D: a method to enhance the accuracy of early prediction of treatment outcome and to inform personalized care. J Clin Psychiatry. 2010;71(11):1502–1508.
14. Li J, Kuk AY, Rush AJ. A practical approach to the early identification of antidepressant medication non-responders. Psychol Med. 2012;42(2):309–316.
15. Lutz W, Lowry J, Kopta SM, Einstein DA, Howard KI. Prediction of dose-response relations based on patient characteristics. J Clin Psychol. 2001;57(7):889–900.
16. Simon GE, Khandker RK, Ichikawa L, Operskalski BH. Recovery from depression predicts lower health services costs. J Clin Psychiatry. 2006;67(8):1226–1231.
17. Gudayol-Ferre E, Herrera-Guzman I, Camarena B, et al. The role of clinical variables, neuropsychological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in major depressive disorder. J Affect Disord. 2010;127(1–3):343–351.
18. Korgaonkar MS, Williams LM, Song YJ, Usherwood T, Grieve SM. Diffusion tensor imaging predictors of treatment outcomes in major depressive disorder. Br J Psychiatry. 2014;205(4):321–328.
19. No authors listed. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry. 2000;157(4 Suppl):1–45.
20. NCCMH. Depression: The Treatment and Management of Depression in Adults (Updated Edition). Leicester and London: The British Psychological Society and the Royal College of Psychiatrists; 2010.
21. Rush AJ, Wisniewski SR, Warden D, et al. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry. 2008;65(8):870–880.
22. Gordon E, Cooper N, Rennie C, Hermens D, Williams LM. Integrative neuroscience: the role of a standardized database. Clin EEG Neurosci. 2005;36(2):64–75.
23. Paul RH, Lawrence J, Williams LM, Richard CC, Cooper N, Gordon E. Preliminary validity of “integneuro”: a new computerized battery of neurocognitive tests. Int J Neurosci. 2005;115(11):1549–1567.
24. Paul RH, Gunstad J, Cooper N, et al. Cross-cultural assessment of neuropsychological performance and electrical brain function measures: additional validation of an international brain database. Int J Neurosci. 2007;117(4):549–568.
25. Williams LM, Mathersul D, Palmer DM, Gur RC, Gur RE, Gordon E. Explicit identification and implicit recognition of facial emotions: I. Age effects in males and females across 10 decades. J Clin Exp Neurpsychol. 2009;31(3):257–277.
26. Williams LM, Rush AJ, Koslow SH, et al. International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol. Trials. 2011;12:4.
27. Rush AJ, Nierenberg A. Mood disorders: Treatment of depression. In: Sadock BJ, Sadock VA, Ruiz P, editors. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry, Ninth Edition. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins; 2009.
28. Maroco J, Silva D, Rodrigues A, Guerreiro M, Santana I, Mendonca A. Data mining methods in the prediction of Dementia: A real-data comparison of the accuracy, sensitivity and specificity of linear discriminate analysis, logistic regression, neural networks, support vector machines, calcification tress and random forests. BMC Research Notes. 2011;4:299.
29. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computer; 2013. Available from: http://www.R-project.org/. Accessed September 25, 2013.
30. Kuhn M. caret: Classification and regression training. R package version 5. 15–7. 2013. Available from: http://CRAN.R-project.org/package=caret. Accessed September 14, 2013.
31. Carstensen B, Plummer M, Laara E, Hills M. Epi: A package for statistical analysis in epidemiology. R package version 1.1.49. 2013. Available from: http://CRAN.R-project.org/package=Epi. Accessed September 14, 2013.
32. Wickham H. ggplot2: elegant graphics for data analysis. New York: Springer; 2009.
33. Dunkin JJ, Leuchter AF, Cook IA, Kasl-Godley JE, Abrams M, Rosenberg-Thompson S. Executive dysfunction predicts nonresponse to fluoxetine in major depression. J Affect Disord. 2000;60(1):13–23.
34. Alexopoulos GS, Kiosses DN, Heo M, Murphy CF, Shanmugham B, Gunning-Dixon F. Executive dysfunction and the course of geriatric depression. Biol Psychiatry. 2005;58(3):204–210.
35. Gorlyn M, Keilp JG, Grunebaum MF, et al. Neuropsychological characteristics as predictors of SSRI treatment response in depressed subjects. J Neural Transm. 2008;115(8):1213–1219.
36. Kampf-Sherf O, Zlotogorski Z, Gilboa A, et al. Neuropsychological functioning in major depression and responsiveness to selective serotonin reuptake inhibitors antidepressants. J Affect Disord. 2004;82(3):453–459.
37. Herrera-Guzman I, Gudayol-Ferre E, Lira-Mandujano J, et al. Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder. Psychiatry Res. 2008;160(1):72–82.
38. Etkin A, Patenaude B, Song Y, et al. A Cognitive-Emotional Biomarker for Predicting Remission with Antidepressant Medications: A Report from the iSPOT-D Trial. Neuropharmacology. In press.
39. Kapur S, Phillips AC, Insel TR. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? Mol Psychiatry. 2012;17(12):1174–1179.
40. Prata D, Mechelli A, Kapur S. Clinically meaningful biomarkers for psychosis: A systematic and quantitative review. Neurosci Biobehav Rev. 2014;45:134–141.